{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Leon-Icaza SA"],"funding":["ZonMW 3R’s","Nuffic Van Gogh Programme","ZonMw","La Région Languedoc-Roussillon","Association Vaincre la Mucoviscidose","CNRS","European Research Council","ANR JCJC ProteasoRegMS","CNRS ATIP avenir and ERC StG","Campus France PHC Van Gogh","Fondation pour la Recherche Médicale","LINK program from the Province of Limburg, the Netherlands","Grégory Lemarchal"],"pagination":["e1011559"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10449475"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(8)"],"pubmed_abstract":["Mycobacterium abscessus (Mabs) drives life-shortening mortality in cystic fibrosis (CF) patients, primarily because of its resistance to chemotherapeutic agents. To date, our knowledge on the host and bacterial determinants driving Mabs pathology in CF patient lung remains rudimentary. Here, we used human airway organoids (AOs) microinjected with smooth (S) or rough (R-)Mabs to evaluate bacteria fitness, host responses to infection, and new treatment efficacy. We show that S Mabs formed biofilm, and R Mabs formed cord serpentines and displayed a higher virulence. While Mabs infection triggers enhanced oxidative stress, pharmacological activation of antioxidant pathways resulted in better control of Mabs growth and reduced virulence. Genetic and pharmacological inhibition of the CFTR is ass"],"journal":["PLoS pathogens"],"pubmed_title":["Druggable redox pathways against Mycobacterium abscessus in cystic fibrosis patient-derived airway organoids."],"pmcid":["PMC10449475"],"funding_grant_id":["IEA 300134","40577ZE","804249","VGP.17/10","AJE20151034460","N°RF20210502852/1/1/48","114021005","FDT202106012794","N° DRTE/RSS - ESR_R&S_DF-000061-2018-003268","INFLAME 804249"],"pubmed_authors":["Aydogan T","Marcoux J","Cam K","Clevers H","Bordignon PJ","Sanchez Dafun A","Berry L","Peters PJ","Guilhot C","Iakobachvili N","Chalut C","Molle V","Meunier E","Bagayoko S","Ferrand C","Cougoule C","Bousquet MP","Rame V","Leon-Icaza SA","Bernard C","Bernes-Lasserre P","Lagarde JM","Murris-Espin M","Mazieres J","Verge R","Mazeres S","Lugo-Villarino G"],"additional_accession":[]},"is_claimable":false,"name":"Druggable redox pathways against Mycobacterium abscessus in cystic fibrosis patient-derived airway organoids.","description":"Mycobacterium abscessus (Mabs) drives life-shortening mortality in cystic fibrosis (CF) patients, primarily because of its resistance to chemotherapeutic agents. To date, our knowledge on the host and bacterial determinants driving Mabs pathology in CF patient lung remains rudimentary. Here, we used human airway organoids (AOs) microinjected with smooth (S) or rough (R-)Mabs to evaluate bacteria fitness, host responses to infection, and new treatment efficacy. We show that S Mabs formed biofilm, and R Mabs formed cord serpentines and displayed a higher virulence. While Mabs infection triggers enhanced oxidative stress, pharmacological activation of antioxidant pathways resulted in better control of Mabs growth and reduced virulence. Genetic and pharmacological inhibition of the CFTR is ass","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2025-04-27T02:38:44.119Z","creation":"2025-04-06T18:41:00.012Z"},"accession":"S-EPMC10449475","cross_references":{"pubmed":["37619220"],"doi":["10.1371/journal.ppat.1011559"]}}